DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2008/0220103 A1 Birnbaum Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2008/0220103 A1 Birnbaum Et Al US 2008022O103A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0220103 A1 Birnbaum et al. (43) Pub. Date: Sep. 11, 2008 (54) METHOD FOR Publication Classification TREATING/CONTROLLING/KILLING FUNG (51) Int. Cl. AND BACTERIA ON LIVING ANIMALS A636/00 (2006.01) A 6LX 36/899 (2006.01) (76) Inventors: Jay Birnbaum, Montville, NJ (US); A636/534 (2006.01) Thomas Blake, Budd Lake, NJ A6IR 36/6 (2006.01) (US); Mahmoud Ghannoum, A636/736 (2006.01) Hudson, OH (US); Steven A63L/045 (2006.01) Vallespir, Park Ridge, NJ (US) A63L/05 (2006.01) A63L/35 (2006.01) Correspondence Address: A63L/II (2006.01) SONNENSCHEN NATH & ROSENTHAL LLP A63L/92 (2006.01) P.O. BOX 061080, WACKER DRIVE STATION, A6II 3/474 (2006.01) SEARS TOWER A63L/35 (2006.01) CHICAGO, IL 60606-1080 (US) A6II 3/165. (2006.01) A6II 3/442 (2006.01) (21) Appl. No.: 12/047,992 A6IP3 L/10 (2006.01) (52) U.S. Cl. ......... 424/735; 424/725; 424/747: 514/739; (22) Filed: Mar. 13, 2008 514/731: 514/729; 514/456; 514/699; 514/570; 514/701: 514/399; 514/655; 514/599; 514/345 Related U.S. Application Data (63) Continuation-in-part of application No. 1 1/541,822, (57) ABSTRACT filed on Oct. 2, 2006. Provided is a method of treating a fungal infection on an animal epidermis, nail or hair, or in an orifice of an animal. (60) Provisional application No. 60/729,624, filed on Oct. The method comprises contacting the fungus infection with a 24, 2005. composition comprising an antifungal botanical. Patent Application Publication Sep. 11, 2008 Sheet 1 of 10 US 2008/022O103 A1 Patent Application Publication Sep. 11, 2008 Sheet 2 of 10 US 2008/022O103 A1 Figure 2 Patent Application Publication Sep. 11, 2008 Sheet 3 of 10 US 2008/022O103 A1 SSSNYSSYSSS SS . - . it.. SR SS &S . SS ''". 8 SS S 3. 8 SS S. l & S : O S S : O Š S ŠES S ESS Patent Application Publication Sep. 11, 2008 Sheet 4 of 10 US 2008/022O103 A1 SSXXXXXXXXXXXXXXXXXXXXXXXXXXXYYXXXYYXXXYYXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXYYXXXYYXXXYYXXXXXS, k (A) 90 70 SO 50 40 10 50 40 30 1O Leather Pretreatment Figure 4 Patent Application Publication Sep. 11, 2008 Sheet 5 of 10 US 2008/022O103 A1 Patent Application Publication Sep. 11, 2008 Sheet 6 of 10 US 2008/022O103 A1 Patent Application Publication Sep. 11, 2008 Sheet 7 of 10 US 2008/022O103 A1 Insole Post-infection treatment S.s S S.S SS. S. S. SS. SS. SS. S S SŠ S Leather Post-infection treatment Figure 7 Patent Application Publication Sep. 11, 2008 Sheet 8 of 10 US 2008/022O103 A1 Patent Application Publication Sep. 11, 2008 Sheet 9 of 10 US 2008/022O103 A1 6ounãIJ £ Patent Application Publication Sep. 11, 2008 Sheet 10 of 10 US 2008/022O103 A1 S SS S& ::$ Fig. 10A. Effect of pretreatment of insoles with (A) 0.01% tolnaftate, (B) 3% tea tree oil, or (C) 0.01% tolnaftate +3% tea tree oil on T. rubrum growth on shoe insoles. Fig. 10B. Effect of post- ment tolnaftate, (B) 3% tea tree oil, or (C) 0.01% tolnaftate +3% tea tree oil on T. rubrunt growth. Figure 10 US 2008/0220 1 03 A1 Sep. 11, 2008 METHOD FOR 0014 Secondary infections that can worsen diaper rash TREATING/CONTROLLING/KILLING FUNG include fungal organisms (for example yeasts of the genus AND BACTERA. ON LIVING ANIMALS Candida). 0015 The above fungi, as well as many other fungi, can CROSS-REFERENCE TO RELATED cause disease in pets and companion animals. The present APPLICATIONS teaching is inclusive of Substrates that contact animals directly or indirectly. Examples of organisms that cause dis 0001. This application is a continuation-in-part of U.S. ease in animals include Malassezia firfir: Epidermophyton patent application Ser. No. 1 1/541,822, filed Oct. 2, 2006, floccosur, Trichophyton mentagrophytes, Trichophyton which claims the benefit of U.S. Provisional Application No. rubrum, Trichophyton tonsurans, Trichophyton equinum, 60/729,624 filed Oct. 24, 2005, both of which are incorpo Dermatophilus congolensis, Microsporum Canis, rated herein by reference in their entirety. Microsporu audouinii, Microsporum gypseum, Malassezia BACKGROUND OF THE INVENTION ovale, Pseudallescheria, Scopulariopsis, Scedosporium, and Candida albicans. 0002 (1) Field of the Invention 0003. The present teachings relate to methods for treating/ BRIEF SUMMARY OF THE INVENTION preventing animal diseases and odors associated with fungi and bacteria on Surfaces or orifices of animals, including the 0016. The inventors have discovered that some botanicals, skin, hair, nails, mouth, nose and vagina of the animal. singly or combined with other antifungal agents, are effective 0004 (2) Description of the Related Art treatments for fungal diseases on Surfaces or orifices of ani 0005 Fungal diseases are some of the most common mals, including the skin, hair, nails, mouth, nose and vagina affecting mammals, and include some of the most common of the animal. The invention is thus directed to a method of infections in man. In humans these include, but are not limited treating a fungal infection on an animal epidermis, nail or tO: hair, or in an orifice of an animal. The method comprises 0006 Tinea corporis—(“ringworm of the body'). This contacting the fungus infection with a composition compris infection causes Small, red spots that grow into large rings ing an antifungal botanical. almost anywhere on the arms, legs, chest, or back. 0007 Tinea pedis fungal infection of the feet. Typically, BRIEF DESCRIPTION OF THE SEVERAL the skin between the toes (interdigital tinea pedis or "Athlete's VIEWS OF THE DRAWINGS foot) or on the bottom and sides of the foot (plantar or “moccasin type' tinea pedis) may be involved. Other areas of 0017 FIG. 1 is photographs of Petri plates showing assays the foot may be involved. for antifungal activity. Panels A and B show a pre-treatment 0008 Onychomycosis—fungal infection of the nail. The assay. In Panel A, active agents showed a clearance Zone most prevalent type is the DSO or Distal Subungual Onycho (arrow) around the biopsy disc, while (Panel B) inactive mycosis. Other types are White Superficial Onychomycosis, agents showed fungal growth around the disc. Panels Cand D Proximal Subungual Onychomycosis, Candidal Onychomy show a post-treatment assay. In Panel C, discs treated with cosis, and Total Dystrophic Onychomycosis. These can be active agents showed no fungal growth. In Panel D inactive caused by various fungi (esp. dermatophytes tinea unguium) agents showed fungal growth on discs. and yeast, including Candida albicans. 0018 FIG. 2 is photographs of Petri plates showing fungal 0009 Dandruff, which is the excessive shedding (exfolia growth assays using (A) CVS Double Air Foam Insoles, (B) tion) of the epidermis of the scalp. A fungus may cause, or Odor eater insoles, (C) CVS Odor Stop Insoles, (D) Dr aggravate, the condition. Scholl's Air Pillow Insoles, (E) Control. None of these com 0010 Tinea cruris: When the fungus grows in the moist, mercial insoles inhibited fungal growth. warm area of the groin, the rash is called tinea cruris. The 0019 FIG. 3 is photographs of Petri plates showing the common name for this infection is “jock itch.” effect of 30% isopropanol on Trichophyton mentagrophytes 0011 Tinea capitis, often called “ringworm of the scalp'. growth on (A) leather and (B) Dr. Scholl's insole. Isopropanol where the hair and scalp is affected, causes itchy, red areas, did not inhibit fungal growth. usually on the head. The hair is often destroyed, leaving bald 0020 FIG. 4 is graphs showing the effect of pretreatment patches. This tinea infection is most common in children, of insoles (A) or leather (B) biopsy discs with different agents although a carrier state has been reported in adults. on growth of dermatophytes. Zone diameter indicates Zone of 0012 Vaginal yeast infections, often caused by an over clearance. growth of a fungus that is a normal vaginal inhabitant, usually 0021 FIG. 5 is photographs of Petri plates showing the Candida albicans and Candida glabrata. effect of pretreatment of insoles with (A) 1% terbinafine. (B) 0013 The list above providing but a few of the most com 1% tolnaftate, or (C) 1% tea tree oil. mon of a long list of Such diseases in one mammal. Many 0022 FIG. 6 is photographs of Petri plates showing the diseases caused by fungi have been identified, and also effect of acetone on the activity of tolnaftate against dermato include Such common disease as oral thrush and diaper rash, phyte growth. Panels A and B shows the growth of T. menta often caused by members of the Candida genus. Fungi are grophytes on insole disc pretreated with (A) acetone or (B) often a complicating factor in diabetic and obese patients. In 4% tolnaftate (w/v. prepared in acetone). Panel C shows the addition, disease inhumans is caused by other fungi including activity of 4% tolnaftate (dissolved in acetone) on already but not limited to those from the genus Aspergillus, Blasto established contamination of T. mentagrophytes. (no fungal myces, Coccidioides, Cryptococcus, Histoplasma, Paracoc regrowth was observed). cidioides, Sporothrix, and at least three genera of Zygo 0023 FIG. 7 is graphs showing the effect of post-infection mycetes, as well as those mentioned below under animals. treatment of insole (A) or leather (B) biopsy discs with dif US 2008/0220 1 03 A1 Sep. 11, 2008 ferent agents on dermatophyte growth. Zone diameter indi natural in origin that possesses antifungal activity as defined. cates Zone of growth. Treatment with 30% isopropanol served "Antifungal compound also includes any Substance that can as vehicle control. destroy/kill/inhibit the growth of fungal spores, for example, 0024 FIG.
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Comparative Evaluation of Isavuconazonium Sulfate
    Van Matre et al. Ann Clin Microbiol Antimicrob (2019) 18:13 https://doi.org/10.1186/s12941-019-0311-3 Annals of Clinical Microbiology and Antimicrobials RESEARCH Open Access Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center Edward T. Van Matre1 , Shelby L. Evans2, Scott W. Mueller3, Robert MacLaren3, Douglas N. Fish3 and Tyree H. Kiser3,4* Abstract Background: Invasive fungal infections are a major cause of morbidity and mortality. Newer antifungals may provide similar efcacy with improved safety compared to older more established treatments. This study aimed to compare clinically relevant safety and efcacy outcomes in real world patients treated with isavuconazole, voriconazole, or posaconazole. Methods: This single center retrospective matched cohort study evaluated adults between January 2015 and Decem- ber 2017. The primary outcome was a composite safety analysis of antifungal related QTc prolongation, elevated liver function tests (> 5 times ULN), or any documented adverse drug event. Key secondary outcomes included: individual safety events, 30-day readmissions, magnitude of drug interactions with immunosuppressive therapy, and overall cost. Results: A total of 100 patients were included: 34 patients in the voriconazole group and 33 patients within each of the isavuconazole and posaconazole groups. The composite safety outcome occurred in 40% of the total cohort and was diferent between isavuconazole (24.2%), voriconazole (55.9%), and posaconazole (39.4%; p 0.028). Change in QTc (p < 0.01) and magnitude of immunosuppression dose reduction (p 0.029) were diferent between= the three groups. No diferences in mortality, length of stay, readmission, or infection= recurrence were observed between groups (p > 0.05 for all).
    [Show full text]
  • New Insights Into the Effect of Amorolfine Nail Lacquer
    Review article New insights into the effect of amorolfine nail lacquer C. Flagothier, C. Pie´ rard-Franchimont and G. E. Pie´ rard Department of Dermatopathology, University Hospital of Lie`ge, Lie`ge, Belgium Summary Despite improvements in antifungal strategies, the outcome of treating onychomycoses often remains uncertain. Several factors account for treatment failure, of which the pharmacokinetics and pharmacodynamics of the antifungal are of importance. The taxonomic nature and ungual location of the fungus cannot be neglected, besides the type of nail and its growth rate. In addition, the biological cycle of the fungus and the metabolic activity of the pathogen likely play a marked influence in drug response. The presence of natural antimicrobial peptides in the nail is also probably a key feature controlling the cure rates. There are many outstanding publications that cover the full spectrum of the field. The purpose of this review is to put in perspective some facets of activity of the topical treatment using amorolfine nail laquer. The antifungal activity of the drug is likely less pronounced in onychomycosis than that expected from conventional in vitro studies. However, the nail laquer formulation should reduce the propensity to form antifungal-resistant spores and limit the risk of reinfection. Key words: amorolfine, antifungal, fungus, onychomycosis, spore. Topical treatments are often considered to be less Introduction efficacious than current oral treatments. However, some During the last 2 decades, the efficacy of treating topical formulations may provide effects that cannot be onychomycoses has been considerably improved by achieved by other treatments. In discussing the treat- the introduction of new generations of potent antifun- ment of onychomycosis, it should not be forgotten that gals.
    [Show full text]
  • Pharmacological Significance of Heterocyclic 1H-Benzimidazole
    Tahlan et al. BMC Chemistry (2019) 13:101 https://doi.org/10.1186/s13065-019-0625-4 BMC Chemistry REVIEW Open Access Pharmacological signifcance of heterocyclic 1H-benzimidazole scafolds: a review Sumit Tahlan, Sanjiv Kumar and Balasubramanian Narasimhan* Abstract Heterocyclic compounds are inevitable in a numerous part of life sciences. These molecules perform various note- worthy functions in nature, medication and innovation. Nitrogen-containing heterocycles exceptionally azoles family are the matter of interest in synthesis attributable to the way that they happen pervasively in pharmacologically dynamic natural products, multipurpose arranged useful materials also profoundly powerful pharmaceuticals and agrochemicals. Benzimidazole moiety is the key building block for several heterocyclic scafolds that play central role in the biologically functioning of essential molecules. They are considered as promising class of bioactive scafolds encompassing diverse varieties of activities like antiprotozoal, antihelminthic, antimalarial, antiviral, anti-infammatory, antimicrobial, anti-mycobacterial and antiparasitic. Therefore in the present review we tried to compile the various pharmacological activities of diferent derivatives of heterocyclic benzimidazole moiety. Keywords: Benzimidazole derivatives, Antiprotozoal activity, Anti-infammatory activity, Antimalarial activity, Antimycobacterial activity, Antiviral activity, Anticancer activity Introduction acetylcholinesterase [4], antiprotozoal [5], anti-infam- Among heterocyclic pharmacophores, the benzimida- matory [6], analgesic [7], antihistaminic [8], antimalarial zole ring system is quite common. Tese substructures [9], antitubercular [10], anti-HIV [11] and antiviral [12]. are often called ‘privileged’ due to their wide recurrence Some of the already synthesized compounds from the in bioactive compounds [1]. Benzimidazole moiety is above mentioned feld have found very strong application a fusion of benzene and imidazole ring system at the 4 in medicine praxis.
    [Show full text]
  • BRAND NAME COMPOSITION Packing Unit BRAND NAME
    BRAND NAME COMPOSITION Packing Unit DOIN-20 SOFT GEL CAP ISOTRETINOIN 20 MG SOFT GEL CAPS 10X1X10 BLISTER FENOGRAS 120 TAB FEXOFENADINE 120MG TABS 10X10 ALU ITRACHEM 100 CAP ITRACONAZOLE 100 MG CAPSULES 10X1X4 STRIP ITRACHEM 200 CAP ITRACONAZOLE 200 MG CAPSULES 10X1X4 STRIP KESHGAIN TABS BIOTIN10MG TABLETS(HAIR GROWTH TABS) 10X1X10 ALU SFLAZA 6 TAB DEFLAZACORT 6MG TABS 10X10 ALU TERBICHEM 250 TAB TERBINAFINE 250MG TABLETS 10X1X7 BLISTER AZYNEX 500 TAB AZITHROMYCIN 500 TAB 10X3 BLISTER BRAND NAME COMPOSITION Packing Unit BEAUTY SOAP WITH ALOE- ALOGLOW SOAP VERA,NEEM,KESAR,SANDAL,TULSI,OLIVE 75GM CARTOON OIL&GLYCERINE KETOLE SOAP KETOCONAZOLE 2% + CERTRIMIDE 0.5% 75GM CARTOON SCABICHEM SOAP PERMETHRIN 5% W/W 75GM CARTOON TRICLOSAN 0.2% + TEA TREE OIL + VIT E 0.4% + ULTRA-SHINE SOAP 75GM CARTOON TITANIUM DIOXIDE SHINE N BEAUTY SOAP NATURAL VIT.E WITH ALOE VERA SOAP 75GM CARTOON BRAND NAME COMPOSITION Packing Unit CALAMINE 15% W/V + ZINC OXIDE 5% W/V + CALACHEM LOTION 100ML CARTOON GLYCERINE 5% W/V CLEANSING LOTION (CETYL ALCOHOL 2.650% CETOCHEM LOTION 100ML CARTOON W/V + STEARYL ALCOHOL 0.260%W/V) CLOBSOL-S LOTION CLOBETASOL + SALICYLIC ACID 3% 50ML CARTOON KETOCONAZOLE 2%W/V + ZINC PYRITHIONE KETOLE-ZPTO SHAMPOO 50ML CARTOON 1%W/W SHAMPOO OCTYL METHOXY CINNAMATE 8% + SWISSGLOW-UV LOTION OXYBENZONE 6.5% + TITANIUM DIOXIDE 0.5% 100ML CARTOON SUNSCREEN LOTION SCABICHEM LOTION PERMETHRIN 5%W/V LOTION 50ML CARTOON BRAND NAME COMPOSITION Packing Unit CLINTOL POWDER CLOTRIMAZOLE 1%W/W POWDER 100GM SHRINK FINNOLE POWDER FLUCONAZOLE 0.5%W/W POWDER
    [Show full text]
  • Candida Auris
    microorganisms Review Candida auris: Epidemiology, Diagnosis, Pathogenesis, Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of Infections in Healthcare Facilities Suhail Ahmad * and Wadha Alfouzan Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait; [email protected] * Correspondence: [email protected]; Tel.: +965-2463-6503 Abstract: Candida auris, a recently recognized, often multidrug-resistant yeast, has become a sig- nificant fungal pathogen due to its ability to cause invasive infections and outbreaks in healthcare facilities which have been difficult to control and treat. The extraordinary abilities of C. auris to easily contaminate the environment around colonized patients and persist for long periods have recently re- sulted in major outbreaks in many countries. C. auris resists elimination by robust cleaning and other decontamination procedures, likely due to the formation of ‘dry’ biofilms. Susceptible hospitalized patients, particularly those with multiple comorbidities in intensive care settings, acquire C. auris rather easily from close contact with C. auris-infected patients, their environment, or the equipment used on colonized patients, often with fatal consequences. This review highlights the lessons learned from recent studies on the epidemiology, diagnosis, pathogenesis, susceptibility, and molecular basis of resistance to antifungal drugs and infection control measures to combat the spread of C. auris Citation: Ahmad, S.; Alfouzan, W. Candida auris: Epidemiology, infections in healthcare facilities. Particular emphasis is given to interventions aiming to prevent new Diagnosis, Pathogenesis, Antifungal infections in healthcare facilities, including the screening of susceptible patients for colonization; the Susceptibility, and Infection Control cleaning and decontamination of the environment, equipment, and colonized patients; and successful Measures to Combat the Spread of approaches to identify and treat infected patients, particularly during outbreaks.
    [Show full text]
  • (Schizotrypanum) Cruzi in Dog Hosts Paulo Marcos Da Matta Guedes,1 Julio A
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2004, p. 4286–4292 Vol. 48, No. 11 0066-4804/04/$08.00ϩ0 DOI: 10.1128/AAC.48.11.4286–4292.2004 Copyright © 2004, American Society for Microbiology. All Rights Reserved. Activity of the New Triazole Derivative Albaconazole against Trypanosoma (Schizotrypanum) cruzi in Dog Hosts Paulo Marcos da Matta Guedes,1 Julio A. Urbina,2 Marta de Lana,3 Luis C. C. Afonso,1 Vanja M. Veloso,1 Washington L. Tafuri,1 George L. L. Machado-Coelho,4 Egler Chiari,5 and Maria Terezinha Bahia1* Departamento de Cieˆncias Biolo´gicas,1 Departamento de Ana´lises Clínicas,3 and Departamento de Farma´cia,4 Universidade Federal de Ouro Preto, Ouro Preto, and Departamento de Parasitologia, Universidade Federal de Minas Gerais, Belo Horizonte,5 Minas Gerais, Brazil, and Centro de Biofísica y Bioquímica, Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela2 Received 25 March 2004/Returned for modification 8 June 2004/Accepted 20 July 2004 Albaconazole is an experimental triazole derivative with potent and broad-spectrum antifungal activity and a remarkably long half-life in dogs, monkeys, and humans. In the present work, we investigated the in vivo activity of this compound against two strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi, the causative agent of Chagas’ disease, using dogs as hosts. The T. cruzi strains used in the study were previously characterized (murine model) as susceptible (strain Berenice-78) and partially resistant (strain Y) to the drugs currently in clinical use, nifurtimox and benznidazole. Our results demonstrated that albaconazole is very effective in suppressing the proliferation of the parasite and preventing the death of infected animals.
    [Show full text]
  • The Management of Common Skin Conditions in General Practice
    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
    [Show full text]
  • Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Anthelmintic Activity of Yeast Particle-Encapsulated Terpenes
    molecules Article Anthelmintic Activity of Yeast Particle-Encapsulated Terpenes Zeynep Mirza 1, Ernesto R. Soto 1 , Yan Hu 1,2, Thanh-Thanh Nguyen 1, David Koch 1, Raffi V. Aroian 1 and Gary R. Ostroff 1,* 1 Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA; [email protected] (Z.M.); [email protected] (E.R.S.); [email protected] (Y.H.); [email protected] (T.-T.N.); [email protected] (D.K.); raffi[email protected] (R.V.A.) 2 Department of Biology, Worcester State University, Worcester, MA 01602, USA * Correspondence: gary.ostroff@umassmed.edu; Tel.: 508-856-1930 Academic Editor: Vaclav Vetvicka Received: 2 June 2020; Accepted: 24 June 2020; Published: 27 June 2020 Abstract: Soil-transmitted nematodes (STN) infect 1–2 billion of the poorest people worldwide. Only benzimidazoles are currently used in mass drug administration, with many instances of reduced activity. Terpenes are a class of compounds with anthelmintic activity. Thymol, a natural monoterpene phenol, was used to help eradicate hookworms in the U.S. South circa 1910. However, the use of terpenes as anthelmintics was discontinued because of adverse side effects associated with high doses and premature stomach absorption. Furthermore, the dose–response activity of specific terpenes against STNs has been understudied. Here we used hollow, porous yeast particles (YPs) to efficiently encapsulate (>95%) high levels of terpenes (52% w/w) and evaluated their anthelmintic activity on hookworms (Ancylostoma ceylanicum), a rodent parasite (Nippostrongylus brasiliensis), and whipworm (Trichuris muris). We identified YP–terpenes that were effective against all three parasites.
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • Step Therapy Criteria Drug Class Topical Antifungal Agents (Brand Products Only)
    STEP THERAPY CRITERIA DRUG CLASS TOPICAL ANTIFUNGAL AGENTS (BRAND PRODUCTS ONLY) BRAND NAME (generic) ECOZA (econazole) ERTACZO (sertaconazole) EXELDERM (sulconazole nitrate) LOPROX (ciclopirox shampoo) LOTRISONE (clotrimazole/betamethasone) LUZU (luliconazole) MENTAX (butenafine) NAFTIN (naftifine) OXISTAT (oxiconazole) VUSION (miconazole/zinc oxide/white petrolatum) XOLEGEL (ketoconazole) Antifungal Topical Step Therapy Policy 06-2017 CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members. CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). ® Registered trademark of the Blue Cross and Blue Shield Association Page 1 of 4 Status: CVS Caremark Criteria Type: Initial Step Therapy; Post Step Therapy Prior Authorization POLICY FDA-APPROVED INDICATIONS Ecoza Ecoza topical 1% foam is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton
    [Show full text]